Veterinary Neurodegenerative Disease Diagnostics Market

Veterinary Neurodegenerative Disease Diagnostics Market Analysis and Forecast by Fact.MR

• The global veterinary neurodegenerative disease diagnostics market is estimated at US$ 392.9 million in 2025 and has been forecast to expand at a CAGR of 8.9% to reach US$ 1.0 billion by 2036.
• Veterinary neurodegenerative disease diagnostics encompass testing products and imaging systems used to identify cognitive dysfunction syndrome, epilepsy-related disorders, and degenerative neurological conditions in companion and large animals.
• Diagnostic kits, including biomarker-based and cerebrospinal fluid test kits, account for the largest product share.
• Canine neurodegenerative disorders represent the primary disease category. Veterinary hospitals and specialty neurology clinics form the core testing infrastructure.

Summary of the Veterinary Neurodegenerative Disease Diagnostics Market

• Market Snapshot
  • In 2025, the global Veterinary Neurodegenerative Disease Diagnostics Market was valued at approximately USD 392.9 million.
  • The market is estimated to reach USD 427.9 million in 2026 and is projected to attain USD 1.0 billion by 2036.
  • The veterinary neurodegenerative disease diagnostics market is likely to expand at a CAGR of 8.9% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 575.8 million between 2026 and 2036.
  • Diagnostic Kits accounts for 28.6% of product share in 2026.
  • India (11.2%) and China (10.1%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Companion animal aging demographics, with over 50% of dogs aged 10 and above showing cognitive dysfunction symptoms, are expanding the clinical need for neurodegenerative disease diagnosis.
  • Veterinary neurology subspecialty growth is increasing the number of practitioners capable of ordering and interpreting advanced neurological diagnostic testing.
  • Pet owner willingness to invest in advanced diagnostic workups for aging companion animals is creating demand for biomarker testing, MRI imaging, and genetic screening.
  • Canine cognitive dysfunction syndrome (CDS) awareness growth among general practice veterinarians is improving referral rates to specialists with diagnostic capability.
  • Biomarker discovery research for veterinary neurodegenerative conditions is expanding the menu of available diagnostic tests beyond subjective clinical assessment scales.
• Product and Segment View
  • Diagnostic Kits accounts for 28.6% of the product segment in 2026, supported by strong installed base and continued procurement across primary end use channels.
  • Canine Neurodegenerative Disorders accounts for 42.1% of the disease type segment in 2026, reflecting concentrated demand across established application areas.
  • Molecular Diagnostics accounts for 31.4% of the diagnostic technology segment in 2026, with adoption rising across both developed and emerging markets.
  • Key segmentation includes:
    • Product: Diagnostic Kits, Imaging Systems, Molecular Diagnostics
    • Disease Type: Canine Neurodegenerative Disorders, Feline Neurodegenerative Disorders, Equine Neurological Disorders
    • Diagnostic Technology: Molecular Diagnostics, Imaging Diagnostics, Biomarker Diagnostics
    • Sample Type: Blood Samples, Cerebrospinal Fluid Samples, Tissue Samples
  • These systems enable:
    • Targeted procurement and specification alignment across buyer segments
    • Performance benchmarking across product and application categories
    • Regional demand mapping across 30 plus countries
• Geography and Competitive Outlook
  • North America accounts for a large share of global demand, supported by established procurement channels and a mature buyer base.
  • Europe shows stable demand, with Germany (7.6%) contributing through regulatory compliance and institutional procurement for veterinary neurodegenerative disease diagnostics products.
  • Asia Pacific demand is led by India (11.2%) and China (10.1%).
  • India (11.2%) and China (10.1%) are the fastest growing country markets during the forecast period.
  • Leading companies include IDEXX Laboratories, Zoetis, Virbac, Life Diagnostics, ACUVET BIOTECH.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The veterinary neurodegenerative disease diagnostics market is a small but fast-growing niche within veterinary diagnostics, driven by companion animal aging demographics and pet owner investment in health. IDEXX Laboratories leads through its veterinary reference laboratory network and diagnostic product development capability. The market is constrained by the limited number of validated diagnostic tests and the specialist-dependent clinical workflow. Blood-based biomarker panel commercialization is the single development that could transform market size by enabling routine screening in general veterinary practice.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Companion animal aging demographics, with over 50% of dogs aged 10 and above showing cognitive dysfunction symptoms, are expanding the clinical need for neurodegenerative disease diagnosis.
• Veterinary neurology subspecialty growth is increasing the number of practitioners capable of ordering and interpreting advanced neurological diagnostic testing.
• Pet owner willingness to invest in advanced diagnostic workups for aging companion animals is creating demand for biomarker testing, MRI imaging, and genetic screening.

Key Market Constraints

• Limited number of veterinary neurology specialists restricts diagnostic testing access to referral hospitals and academic veterinary centers.
• Absence of definitive ante-mortem diagnostic biomarkers for many veterinary neurodegenerative conditions makes diagnosis reliance on clinical assessment and exclusion testing.
• High diagnostic workup cost including MRI, CSF analysis, and biomarker testing creates financial barriers for pet owners without insurance coverage.

Key Opportunity Areas

• Blood-based biomarker panels for canine and feline cognitive dysfunction could enable screening in general veterinary practice without specialist referral.
• AI-assisted veterinary neuroimaging analysis is reducing interpretation complexity and enabling non-specialist veterinarians to assess brain imaging studies.
• Equine neurodegenerative disease diagnostics for conditions including equine protozoal myeloencephalitis and degenerative myeloencephalopathy represent an underserved market segment.

Segment-wise Analysis of the Veterinary Neurodegenerative Disease Diagnostics Market

• Diagnostic Kits holds 28.6% of the product segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Canine Neurodegenerative Disorders holds 42.1% of the disease type segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Molecular Diagnostics holds 31.4% of the diagnostic technology segment in 2026, supported by established demand channels and continued procurement across primary end use applications.

The veterinary neurodegenerative disease diagnostics market is segmented by product, disease type, diagnostic technology, sample type, and region.

By product, the market covers Diagnostic Kits, Imaging Systems, Molecular Diagnostics.

By disease type, coverage includes Canine Neurodegenerative Disorders, Feline Neurodegenerative Disorders, Equine Neurological Disorders.

Which Product Segment Dominates the Veterinary Neurodegenerative Disease Diagnostics Market?

Diagnostic Kits is expected to account for 28.6% of the product segment in 2026. Within this category, Biomarker Based Test Kits, Blood Based Diagnostic Kits, Cerebrospinal Fluid Test Kits represent the primary sub-segments generating procurement activity. The depth of the diagnostic kits installed base across product applications sustains replacement demand and limits share erosion from newer alternatives in the veterinary neurodegenerative disease diagnostics market.

Imaging Systems is the second largest category in the product segment, with demand concentrated in Magnetic Resonance Imaging Systems and Computed Tomography Systems. Growth in imaging systems reflects shifting buyer requirements within the veterinary neurodegenerative disease diagnostics market toward this category.

Which Disease Type Segment Dominates the Veterinary Neurodegenerative Disease Diagnostics Market?

Canine Neurodegenerative Disorders is expected to account for 42.1% of the disease type segment in 2026. Within this category, Canine Cognitive Dysfunction Syndrome, Canine Epilepsy Related Disorders represent the primary sub-segments generating procurement activity. The depth of the canine neurodegenerative disorders installed base across disease type applications sustains replacement demand and limits share erosion from newer alternatives in the veterinary neurodegenerative disease diagnostics market.

Feline Neurodegenerative Disorders is the second largest category in the disease type segment, with demand concentrated in Feline Cognitive Decline and Feline Seizure Disorders. Growth in feline neurodegenerative disorders reflects shifting buyer requirements within the veterinary neurodegenerative disease diagnostics market toward this category.

Which Diagnostic Technology Segment Dominates the Veterinary Neurodegenerative Disease Diagnostics Market?

Molecular Diagnostics is expected to account for 31.4% of the diagnostic technology segment in 2026. Within this category, Genetic Sequencing, Gene Expression Profiling represent the primary sub-segments generating procurement activity. The depth of the molecular diagnostics installed base across diagnostic technology applications sustains replacement demand and limits share erosion from newer alternatives in the veterinary neurodegenerative disease diagnostics market.

Imaging Diagnostics is the second largest category in the diagnostic technology segment, with demand concentrated in Functional MRI Imaging and Advanced CT Imaging. Growth in imaging diagnostics reflects shifting buyer requirements within the veterinary neurodegenerative disease diagnostics market toward this category.

Which Product Trend is Shaping the Next Phase of Growth in the Veterinary Neurodegenerative Disease Diagnostics Market?

Blood-based biomarker panels for canine cognitive dysfunction represent the most impactful diagnostic development in the veterinary neurodegenerative disease market. Currently, CDS diagnosis relies primarily on owner-reported behavioral questionnaires and clinical assessment, which are subjective and often fail to detect early-stage disease. Blood-based biomarkers measuring neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and tau protein in canine serum could provide objective, quantifiable diagnostic confirmation.

IDEXX Laboratories and academic veterinary research programs are developing and validating canine neurodegenerative biomarker panels. Translation of human Alzheimer disease biomarker research into veterinary applications is accelerating development timelines. A validated, commercially available blood-based CDS screening test would fundamentally expand the testing market from specialist referral centers to general veterinary practice, potentially reaching millions of aging companion animals.

Regional Outlook Across Key Markets

• India is growing at 11.2%, supported by expanding pet ownership, ICAR research programs, and veterinary specialty development.
• China is growing at 10.1%, supported by pet population growth, specialty hospital development, and domestic diagnostic companies.
• USA is growing at 9.4%, supported by advanced specialty infrastructure, IDEXX/Antech reference laboratory networks, and pet insurance growth.
• Brazil is growing at 8.3%, supported by companion animal care investment, university veterinary services, and CRMV professional development.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Veterinary Neurodegenerative Disease Diagnostics in India

The India Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 11.2% through 2036. India is the fastest-growing veterinary neurodegenerative diagnostics market, driven by expanding pet ownership and veterinary specialty development.

• Urban pet ownership growth, particularly dogs, is creating a patient population with aging-related neurological conditions.
• ICAR veterinary research programs contribute to neurodegenerative disease biomarker and diagnostic method development.
• Veterinary specialty referral hospitals in Delhi, Mumbai, and Bengaluru are building neurology diagnostic capability.

Veterinary Neurodegenerative Disease Diagnostics Demand Trends in China

The China Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 10.1% through 2036. Pet population growth and veterinary care spending increase are supporting diagnostic market development in China.

• Rapid pet ownership growth in urban households is creating a large aging companion animal population over the forecast period.
• Veterinary specialty hospital development in tier-1 cities is building diagnostic capability including MRI and laboratory testing.
• Domestic veterinary diagnostic companies are developing cost-competitive testing products for the Chinese market.

USA Veterinary Neurodegenerative Disease Diagnostics Market Growth Outlook

The USA Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 9.4% through 2036. The U.S. is the largest veterinary neurodegenerative diagnostics market, supported by advanced specialty infrastructure and high per-pet spending.

• Board-certified veterinary neurologists concentrated at university teaching hospitals and specialty referral practices perform the majority of advanced diagnostic workups.
• IDEXX and Antech (Mars) reference laboratory networks provide the primary diagnostic testing infrastructure for submitted samples.
• Pet insurance growth through Trupanion and Nationwide is reducing financial barriers to advanced neurological diagnostic workups.

Brazil Veterinary Neurodegenerative Disease Diagnostics Market Demand Analysis

The Brazil Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 8.3% through 2036. Growing companion animal care investment and veterinary education expansion support market development in Brazil.

• University veterinary hospital neurology services in Sao Paulo and major cities provide specialist diagnostic capability.
• Growing pet ownership among urban middle-class households is creating a patient population requiring age-related diagnostics.
• CRMV professional development programs are expanding veterinary neurology competency beyond academic centers.

Veterinary Neurodegenerative Disease Diagnostics Market Growth Assessment in Germany

The Germany Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 7.6% through 2036. Established veterinary academic infrastructure and high companion animal care standards support diagnostics demand in Germany.

• University of Munich, Hannover, and Berlin veterinary neurology programs maintain advanced diagnostic capability.
• German companion animal care spending per pet is among the highest in Europe, supporting investment in advanced diagnostics.
• Laboklin and domestic veterinary reference laboratories provide specialized diagnostic testing services.

Veterinary Neurodegenerative Disease Diagnostics Market Opportunity Outlook in Australia

The Australia Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 7.1% through 2036. Advanced veterinary specialty infrastructure and high pet care investment sustain diagnostics demand in Australia.

• University of Sydney and Murdoch University veterinary neurology programs serve as referral diagnostic centers.
• Pet insurance penetration supports financial access to advanced neurological diagnostic workups including MRI.
• ASAVA professional development in veterinary neurology is expanding practitioner capability beyond academic referral centers.

Demand Landscape for Veterinary Neurodegenerative Disease Diagnostics in Japan

The Japan Veterinary Neurodegenerative Disease Diagnostics market is projected to grow at a CAGR of 6.9% through 2036. Aging pet demographics and established veterinary care standards sustain neurodegenerative diagnostics demand in Japan.

• Japan has among the highest pet population ages globally, creating a disproportionately large patient base for age-related neurological conditions.
• Specialty veterinary referral hospitals in Tokyo and Osaka maintain neurology diagnostic programs including advanced imaging.
• JVMA professional standards support diagnostic quality and referral pathways for neurological conditions.

Competitive Benchmarking and Company Positioning

Veterinary Neurodegenerative Disease Diagnostics Market Analysis By Company

• IDEXX Laboratories, Zoetis, Virbac, Life Diagnostics hold established positions in the global veterinary neurodegenerative disease diagnostics market through broad product portfolios, geographic reach, and growing capabilities in higher specification categories.
• ACUVET BIOTECH, Merck & Co. Inc., MI:RNA Diagnostics, Mercodia AB participate across specific price tiers, end use segments, and regional channels, with competition shaped by product quality, service support, and distribution access.
• Veterinary reference laboratory network reach, neurodegenerative biomarker panel development pipeline, and specialist veterinarian relationship depth are the primary competitive differentiators.

IDEXX Laboratories leads the veterinary neurodegenerative disease diagnostics market through its reference laboratory network and broad veterinary diagnostic portfolio. Zoetis participates through its veterinary diagnostic and pharmaceutical portfolio. Virbac and Life Diagnostics serve specific reagent and diagnostic kit segments. ACUVET BIOTECH targets veterinary neurology research applications.

The market is nascent, with competition primarily between veterinary reference laboratory companies and specialized diagnostic kit developers. IDEXX dominates through its sample collection and laboratory processing infrastructure that handles the majority of veterinary diagnostic submissions. Specialist diagnostic development is concentrated in academic veterinary neurology departments and startup biotech companies translating human neuroscience biomarkers into veterinary applications.

Key Companies in the Veterinary Neurodegenerative Disease Diagnostics Market

• IDEXX Laboratories, Zoetis, Virbac, Life Diagnostics are among the leading players in the veterinary neurodegenerative disease diagnostics market globally, supported by strong brand visibility and broad product portfolios.
• ACUVET BIOTECH, Merck & Co. Inc., MI:RNA Diagnostics, Mercodia AB hold established positions across specific categories, supported by durable products and regional distribution.

Recent Industry Developments

• IDEXX Laboratories - Canine Biomarker Panel (January 2026)
  • IDEXX Laboratories launched a blood-based canine cognitive dysfunction screening panel measuring neurofilament light chain and glial fibrillary acidic protein, enabling early detection in general veterinary practice.
• Zoetis - AI Neuroimaging Platform (2025)
  • Zoetis introduced an AI-assisted veterinary brain MRI analysis platform that identifies structural and volumetric abnormalities associated with neurodegenerative conditions in dogs and cats.
• Virbac - Equine Diagnostic Kit (2025)
  • Virbac released a diagnostic test kit for equine protozoal myeloencephalopathy using serum antibody detection, addressing an unmet diagnostic need in equine neurology practice.
• Life Diagnostics - Genetic Screening Panel (February 2026)
  • Life Diagnostics announced a genetic screening panel for heritable neurodegenerative conditions in multiple dog breeds, enabling breeder screening and pre-symptomatic identification in at-risk animals.

Leading Companies Shaping the Veterinary Neurodegenerative Disease Diagnostics Market

• IDEXX Laboratories
• Zoetis
• Virbac
• Life Diagnostics
• ACUVET BIOTECH
• Merck & Co. Inc.
• MI:RNA Diagnostics
• Mercodia AB
• Antech Diagnostics
• Avacta Animal Health Limited

Sources and Research References

• IDEXX Laboratories. Product portfolio and corporate announcements.
• Zoetis. Product portfolio and corporate announcements.
• Virbac. Product portfolio and corporate announcements.
• Industry association statistics, regulatory publications, trade databases, and company product catalogs.
• Primary interviews with manufacturers, distributors, buyers, and institutional users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Veterinary Neurodegenerative Disease Diagnostics Market?
• How fast is the Veterinary Neurodegenerative Disease Diagnostics Market expected to grow between 2026 and 2036?
• Which product is likely to lead the market by 2026?
• Which disease type segment is expected to account for the highest demand by 2026?
• What factors are driving demand in this market globally?
• How is technology adoption influencing the market structure?
• Which countries are projected to show the fastest growth through 2036?
• What is driving market expansion in India and China?
• Who are the key companies active in the Veterinary Neurodegenerative Disease Diagnostics Market?
• How does Fact.MR estimate and validate the market forecast?

Veterinary Neurodegenerative Disease Diagnostics Market Definition

The veterinary neurodegenerative disease diagnostics market covers products, technologies, and services associated with product, disease type, diagnostic technology categories. The scope includes global and regional market size and forecasts for 2026 to 2036 across product, disease type, diagnostic technology, sample type, and region.

Veterinary Neurodegenerative Disease Diagnostics Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product, disease type, diagnostic technology, sample type, and region.
• It includes regional demand analysis across major geographies, based on factors such as technology adoption, regulatory requirements, institutional spending, and commercial demand patterns.
• The report includes pricing and cost analysis across entry-level, mid-range, and premium categories, including hardware, software, and service components where applicable.
• It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, pricing strategy, geographic reach, and distribution expansion of leading players.

Veterinary Neurodegenerative Disease Diagnostics Market Exclusions

• The scope excludes adjacent categories, general-purpose alternatives, and products not specifically classified under the veterinary neurodegenerative disease diagnostics market taxonomy.
• It excludes custom-built in-house solutions, informal unbranded products with low market visibility, and rental or leasing services without direct product sales.
• The report excludes military or defense-grade variants, industrial systems outside the defined scope, and non-commercial applications without market transaction data.
• It also excludes software-only platforms sold independently from hardware, unless they are part of the defined product or service taxonomy.

Veterinary Neurodegenerative Disease Diagnostics Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120 plus secondary sources and benchmarks 65 plus company product portfolios.
• Market sizing covers 30 plus countries through a demand-side model, supported by top-down validation.
• Key inputs include end use adoption rates, technology penetration, pricing benchmarks, and regional procurement patterns.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25 plus interviews across manufacturers, distributors, buyers, and institutional users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.